VCM
OCUL icon

Voleon Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Voleon Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,822
Closed -$265K – 876
2025
Q4 		$265K Sell
21,822
-11,381
-34% -$138K 0.01% 685
2025
Q3 		$388K Buy
+33,203
New +$397K 0.01% 652

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Voleon Capital Management's OCUL Position: Q1 2026 in Review

Voleon Capital Management sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 21,822 shares — an estimated $265K sold.

Voleon Capital Management first reported a position in OCUL in Q3 2025 and held it in 2 quarters. The position peaked at $388K in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Voleon Capital Management reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Voleon Capital Management sold 21,822 Ocular Therapeutix shares in Q1 2026, an estimated $265K.
  • Voleon Capital Management first reported a position in Ocular Therapeutix in Q3 2025 and held it in 2 quarters.
  • Voleon Capital Management's Ocular Therapeutix position peaked at $388K in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.